Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

3.90
+0.07501.96%
Volume:95.57K
Turnover:373.45K
Market Cap:26.32M
PE:-0.71
High:3.98
Open:3.85
Low:3.84
Close:3.82
52wk High:6.01
52wk Low:3.20
Shares:6.76M
Float Shares:5.60M
Volume Ratio:0.55
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4689
EPS(LYR):-10.1953
ROE:-275.85%
ROA:-106.65%
PB:7.58
PE(LYR):-0.38

Loading ...

Cingulate Is Maintained at Buy by Roth Capital

Dow Jones
·
Oct 16

Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success

TIPRANKS
·
Oct 15

Cingulate price target raised to $17 from $10 at Roth Capital

TIPRANKS
·
Oct 15

FDA Accepts Cingulate’s New Drug Application for Ctx-1301 in Attention-Deficit/Hyperactivity Disorder (Adhd) and Sets a May 31, 2026 Pdufa Date

THOMSON REUTERS
·
Oct 14

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

GlobeNewswire
·
Oct 14

Cingulate Inc Approves Stock Issuance Proposal

TIPRANKS
·
Sep 26

Cingulate Inc. Held Special Meeting of Stockholders

Reuters
·
Sep 26

Cingulate Inc.’s Strategic Advances and Market Potential Reinforce Buy Rating

TIPRANKS
·
Sep 19

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Cingulate Inc (CING)

TIPRANKS
·
Sep 18

Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences

TIPRANKS
·
Sep 17

Cingulate Inc - Bend Bio Sciences to Manufacture Ctx-1301 in U.S. Through 2028

THOMSON REUTERS
·
Sep 17

Cingulate Inc: to Purchase 100% of Co's Overall U.S. Commercial Supply of Ctx-1301 From Bend

THOMSON REUTERS
·
Sep 17

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

GlobeNewswire
·
Sep 17

Cingulate Inc. Issues Over 325,000 Shares in Debt Exchange Transactions from July to September 2025

Reuters
·
Sep 06

Cingulate Inc. Appoints John A. Roberts as Executive Chairman, CEO Shane Schaffer Placed on Administrative Leave

Reuters
·
Aug 29

Cingulate Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Aug 22

Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlighting Progress Towards ADHD Asset Launch

Reuters
·
Aug 22

Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate

Benzinga
·
Aug 19

Cingulate Q2 Net Income USD -4.8 Million VS. Ibes Estimate USD -3.27 Million

THOMSON REUTERS
·
Aug 19

Press Release: Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Dow Jones
·
Aug 19